Single Arm on the Tolerability of Weekly Nab-paclitaxel
Status:
Completed
Trial end date:
2019-07-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of weekly nab-paclitaxel for
a second-line treatment in elderly subjects, 70 years of age or greater, with non-small cell
lung cancer (NSCLC)